{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:37:40Z","timestamp":1787071060009,"version":"build-2736575974"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Ectopic production of amylase by tumor cells is known since 1951. Elevated amylase in multiple myeloma (MM) was first described in 1988. It has been postulated that translocation of chromosome 1, where amylase gene is situated, is responsible for ectopic production from the malignant plasma cells. Anecdotal reports have shown hyperamylasemia in MM to be associated with extensive bone disease, rapid progression, and shorter survival. Serum amylase estimation is a ubiquitous test. This prospective study was conducted to ascertain the degree of elevated amylase, its clinical utility, and implications in MM patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>In an 18-month period, all consenting patients with newly diagnosed or relapsed MM were tested for serum amylase levels. The study excluded patients with elevated lipase, abnormal creatinine clearance, and evidence of intestinal obstruction or perforation. Patients with amylase value &gt;100 U\/L were designated to have \u201celevated amylase level\u201d for the purpose of this study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      We enrolled 58 patients with MM, of which 29.3% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 17) were found to have elevated serum amylase levels. The median age of patients with elevated amylase was 65 years. The male-to-female ratio was 1.9:1. There was no statistical association between age, gender, type of heavy chain class, light chain, or high-risk cytogenetics. Among patients with the International Staging System (ISS), Stages I, II, and III, 20.8% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 5), 31.3% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 5), and 41.2% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 7) were noted to have elevated amylase levels. A statistically significant association was noted between the presence of extramedullary disease (EMD) and elevated amylase level (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.028). Higher mortality (29.4% versus 17%) and shorter mean survival of (30.2 \u00b1 3.3 months versus 51.7 + 4.9 months) were recorded in patients with elevated amylase levels in comparison to those with normal levels.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Elevated serum amylase level in MM is indicative of advanced ISS stage, the presence of EMD, higher risk of mortality, and shorter survival. Serum amylase can be used as a cost-effective tool in myeloma management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_2143_21","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T08:01:28Z","timestamp":1695196888000},"page":"1231-1235","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["The utility of serum amylase as a prognostic marker in multiple myeloma"],"prefix":"10.4103","volume":"19","author":[{"given":"Sree Vamsee","family":"Chetana Panthula","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Amrita Institute of Medical Science, Kochi, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajitha","family":"Krishnan","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Amrita Institute of Medical Science, Kochi, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley M.","family":"Jose","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Amrita Institute of Medical Science, Kochi, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,7,20]]},"reference":[{"key":"R1-20241021","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/BF01534909","article-title":"Regional assignment of human amylase (AMY) to p22----p21 of chromosome 1","volume":"10","author":"Tricoli","year":"1984","journal-title":"Somat Cell Mol Genet"},{"key":"R2-20241021","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3109\/10408368509165786","article-title":"Biochemistry of human alpha amylase isoenzymes","volume":"21","author":"Zakowski","year":"1985","journal-title":"Crit Rev Clin Lab Sci"},{"key":"R3-20241021","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/ajcp\/21.11.1057","article-title":"Elevated serum amylase associated with bronchogenic carcinoma;report of case","volume":"21","author":"Weiss","year":"1951","journal-title":"Am J Clin Pathol"},{"key":"R4-20241021","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/1097-0142(197704)39:4<1656::AID-CNCR2820390440>3.0.CO;2-8","article-title":"Amylase in the lung","volume":"39","author":"Otsuki","year":"1977","journal-title":"Cancer"},{"key":"R5-20241021","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1093\/clinchem\/24.7.1207","article-title":"Marked hyperamylasemia associated with carcinoma of the lung","volume":"24","author":"Flood","year":"1978","journal-title":"Clin Chem"},{"key":"R6-20241021","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/0004563213510490","article-title":"Hyperamylasaemia:Don't forget undiagnosed carcinoma","volume":"51","author":"Crook","year":"2014","journal-title":"Ann Clin Biochem"},{"key":"R7-20241021","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1200\/JCO.2004.11.099","article-title":"Challenging problems in malignancy:case 1. Presentation of small-cell lung cancer with marked hyperamylasemia","volume":"22","author":"Benedetti","year":"2004","journal-title":"J Clin Oncol"},{"key":"R8-20241021","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/1097-0142(196003\/04)13:2<283::AID-CNCR2820130212>3.0.CO;2-2","article-title":"Studies of amylase activity in pleural effusions and ascites","volume":"13","author":"Ende","year":"1960","journal-title":"Cancer"},{"key":"R9-20241021","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1093\/clinchem\/25.6.948","article-title":"Hyperamylasemia and ovarian carcinoma","volume":"25","author":"Sandiford","year":"1979","journal-title":"Clin Chem"},{"key":"R10-20241021","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1136\/ijgc-00009577-200403000-00029","article-title":"Complete remission of ovarian endometrioid adenocarcinoma associated with hyperamylasemia and liver metastasis treated by paclitaxel and carboplatin chemotherapy:A case report","volume":"14","author":"Tohya","year":"2004","journal-title":"Int J Gynecol Cancer"},{"key":"R11-20241021","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.gynor.2012.06.002","article-title":"Amylase-producing ovarian carcinoma:A case report and a retrospective study","volume":"2","author":"Kawakita","year":"2012","journal-title":"Gynecol Oncol Case Rep"},{"key":"R12-20241021","doi-asserted-by":"crossref","first-page":"e13520","DOI":"10.1097\/MD.0000000000013520","article-title":"Hyperamylasemia may indicate the presence of ovarian carcinoma:A case report","volume":"97","author":"Guo","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"R14-20241021","first-page":"172","article-title":"Acase of pheochromocytoma with hyperamylasemia","volume":"42","author":"Kim","year":"2003","journal-title":"Korean J Gastroenterol"},{"key":"R15-20241021","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/0016-5085(88)90447-7","article-title":"A unique case of breast carcinoma producing pancreatic-type isoamylase","volume":"94","author":"Weitzel","year":"1988","journal-title":"Gastroenterology"},{"key":"R16-20241021","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF01600149","article-title":"Immunohistochemical, ultrastructural and biochemical studies of an amylase-producing breast carcinoma","volume":"419","author":"Inaji","year":"1991","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"key":"R17-20241021","first-page":"351","article-title":"Serum amylase and isoamylases in malignant bone tumors","volume":"31","author":"M\u00e4siar","year":"1984","journal-title":"Neoplasma"},{"key":"R18-20241021","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/1097-0142(19881015)62:8<1511::AID-CNCR2820620811>3.0.CO;2-L","article-title":"Ectopic production of salivary-type amylase by a IgA-lambda-type multiple myeloma","volume":"62","author":"Hata","year":"1988","journal-title":"Cancer"},{"key":"R19-20241021","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000204384","article-title":"Amylase-producing Bence Jones multiple myeloma with pancreatitis-like symptoms","volume":"90","author":"Lopez","year":"1993","journal-title":"Acta Haematol"},{"key":"R20-20241021","first-page":"246","article-title":"Genetic analysis of amylase-producing cell lines:Ectopic activation of the amylase gene by translocation","volume":"20","author":"Hata","year":"1990","journal-title":"Jpn J Clin Oncol"},{"key":"R21-20241021","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.cca.2006.08.002","article-title":"Multiple myeloma associated with sialyl salivary-type amylase","volume":"376","author":"Shigemura","year":"2007","journal-title":"Clin Chim Acta"},{"key":"R22-20241021","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1177\/000456320203900615","article-title":"Hyperamylasaemia and multiple myeloma","volume":"39","author":"Ross","year":"2002","journal-title":"Ann Clin Biochem"},{"key":"R23-20241021","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/10428190500262144","article-title":"Amylase:A disease activity index in multiple myeloma?","volume":"47","author":"Pinelli","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"R24-20241021","first-page":"952","article-title":"Amylase-producing multiple myeloma","volume":"115","author":"Fujii","year":"1991","journal-title":"Arch Pathol Lab Med"},{"key":"R25-20241021","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000100931","article-title":"Paraneoplastic hyperamylasaemia in association with multiple myeloma","volume":"117","author":"Calvo-Villas","year":"2007","journal-title":"Acta Haematol"},{"key":"R26-20241021","first-page":"158","article-title":"Amylase-producing IgG kappa type multiple myeloma","volume":"37","author":"Kim","year":"2002","journal-title":"Korean J Hematol"},{"key":"R27-20241021","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1200\/JCO.2012.46.4677","article-title":"Salivary amylase-producing multiple myeloma:Case report and review of the current literature","volume":"31","author":"Sosnoff","year":"2013","journal-title":"J Clin Oncol"},{"key":"R28-20241021","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1200\/JCO.1994.12.11.2398","article-title":"Immunoglobulin D multiple myeloma:Presenting features, response to therapy, and survival in a series of 53 cases","volume":"12","author":"Blad\u00e9","year":"1994","journal-title":"J Clin Oncol"},{"key":"R29-20241021","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1046\/j.1365-2141.1996.5191061.x","article-title":"Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years","volume":"93","author":"Blad\u00e9","year":"1996","journal-title":"Br J Haematol"},{"key":"R30-20241021","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/ajh.23731","article-title":"Clinical profiles of multiple myeloma in Asia \u2013An Asian myeloma network study","volume":"89","author":"Kim","year":"2014","journal-title":"Am J Hematol"},{"key":"R31-20241021","first-page":"686","article-title":"Ectopic salivary amylase-producing IgA- lambda-type multiple myeloma with expression of MDR-1\/P-glycoprotein","volume":"32","author":"Natazuka","year":"1991","journal-title":"Rinsho Ketsueki"},{"key":"R32-20241021","first-page":"1484","article-title":"Amylase-producing multiple myeloma:A case report","volume":"48","author":"Mori","year":"2007","journal-title":"Rinsho Ketsueki"},{"key":"R33-20241021","first-page":"1022","article-title":"Ectopic production of amylase by a non-producing type of multiple myeloma","volume":"31","author":"Wada","year":"1990","journal-title":"Rinsho Ketsueki"},{"key":"R34-20241021","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/RLU.0b013e31825b2071","article-title":"FDG PET or PET\/CT for detecting intramedullary and extramedullary lesions in multiple myeloma:A systematic review and meta-analysis","volume":"37","author":"Lu","year":"2012","journal-title":"Clin Nucl Med"},{"key":"R35-20241021","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/annonc\/mdp329","article-title":"Incidence, presenting features and outcome of extramedullary disease in multiple myeloma:A longitudinal study on 1003 consecutive patients","volume":"21","author":"Varettoni","year":"2010","journal-title":"Ann Oncol"},{"key":"R36-20241021","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1515\/tjb-2016-0152","article-title":"A rare cause of hyperamylasemia:Multiple myeloma","volume":"41","author":"Sincan","year":"2016","journal-title":"Turk J Biochem"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_2143_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:40:55Z","timestamp":1787067655000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_2143_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,20]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_2143_21","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,20]]},"assertion":[{"value":"2021-11-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}